Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics

Next Previous
Drug Profile

Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics

Alternative Names: BMS-914143; Lambda - Eiger BioPharmaceuticals; PEG-IL-29 - ZymoGenetics; PEG-interferon lambda; PEG-interleukin-29 - ZymoGenetics; PEG-rIL-29 - ZymoGenetics; Peginterferon lambda-1a - Eiger BioPharmaceuticals/ZymoGenetics; Pegylated interferon lambda - Eiger BioPharmaceuticals

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Bristol-Myers Squibb; Eiger BioPharmaceuticals, Inc.; University Health Network; ZymoGenetics
  • Class Antivirals; Interferons; Interleukins
  • Mechanism of Action Interleukin 29 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III COVID 2019 infections; Hepatitis D
  • No development reported Multiple sclerosis
  • Discontinued Cancer; Hepatitis B; Hepatitis C

Most Recent Events

  • 31 Dec 2023 Eiger BioPharmaceuticals has patent protection for peginterferon lambda 1a in USA and Europe
  • 31 Dec 2023 Eiger BioPharmaceuticals has patents pending for peginterferon lambda 1a in multiple countries worldwide
  • 31 Dec 2023 Eiger Biopharmaceuticals plans to file BLA for Peginterferon lambda 1a for COVID-2019 infections and Hepatitis D
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top